Why Lifecore Biomedical, Inc.’s (LFCR) Stock Is Up 5.97%
As of Thursday, July 16, Lifecore Biomedical, Inc.’s LFCR share price has surged by 5.97%, which has investors questioning if this is right time to sell.Michael Rose
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Cynthia McLaughlin
Cynthia McLaughlin
Michael Rose
Cynthia McLaughlin
| Share Statistics | LFCR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $165.8 | $1,790.4 | 26% |
|
| Shares Out (Mil) | 37.5 | 94.8 | 42% |
|
| Institutional Ownership | 90.0% | 90.0% | 58% |
|
| Float (Mil) | 19.4 | 69.9 | 29% |
|
| Beta | 1.06 | 1.20 | 63% |
|
| Avg Daily Volume (000s) | 137 | 814 | 39% |
|
| Price Change (52-week) |
(37.8%) | 80.2% | 20% |
|
| Growth | LFCR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 5.1% | 7.8% | 37% |
|
| Net Income (5yr) | 11.0% | (13.7%) | 57% |
|
| EPS (5yr) | 13.3% | 0.7% | 52 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 76.2% | (15.0%) | 97% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | 2 | |
| Current EPS | na | na | ($0.890) | |
| Month Ago EPS | na | na | ($0.810) | |
| # Rev Up | na | na | 0 | |
| # Rev Down | na | na | 0 | |
| Three Months Ago EPS | na | na | ($0.860) | |
| Year/Year Chg | na | na | na | |
| Financials | LFCR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $130 | $785 | 29% |
|
| Net Income (TTM) (Mil) | ($31) | ($14) | 20% |
|
| EPS (TTM) | ($0.923) | ($0.200) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | $13 | $53 | 39% |
|
| Net Cash Flow (TTM) (Mil) | $1 | ($4) | 46% |
|
| Long-Term Debt (Q1) (Mil) | $149 | $270 | 47% |
|
| Enterprise Value (Q1) (Mil) | $361 | $2,444 | 31% |
|
| Valuation | LFCR | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.92 | na |
|
| P/E | na | 43.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.3 | na |
|
| Ratios | LFCR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 31.4% | 47.6% | 37% |
|
| Net Margin | (23.8%) | (2.9%) | 16% |
|
| ROA | (12.8%) | (2.8%) | 24% |
|
| ROE | 474.1% | (4.5%) | 99% |
|
| Liabilities to Assets | 90.8% | 43.0% | 87% |
|
| F-Score | 3 | 5 | 19% |
|
Lifecore Biomedical, Inc. did not pass any screens on 7/31/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors